| abstract |
The disclosure relates to compounds of formula (I); wherein, the crossing dashed line illustrates the bond formed joining R1 to the molecule of formula (I); R is H, R5C(O), R5CH2OC(O), or R5CH2NHC(O); R2 and R3 are independently OH or H, provided that R2 and R3 are not simultaneously OH; R4 is H, R5C(O), R5CH2OC(O), or R5CH2NHC(O), provided that R and R4 are not simultaneously H; R5 has the general formula: CH3-(CH2)n-(CH=CH-CH2)m-CH=CH-(CH2)k-; k is 4; m is 0 or 1; and n is an integer from 0 to 10, or a pharmaceutical salt thereof. These compounds are suitable for treating a neoplastic condition such as a cancerous disease selected from leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome, solid tumour or a hematological cancer or malignancy, wherein the solid tumour may be a cancer of a tissue selected from the group consisting of breast, ovary, prostate, brain, bladder, and lung. These compounds are also suitable for treating an inflammatory condition selected from inflammatory state of the lung, connective tissue, gastro-intestinal tract, or vasculature. |